FIELD: medicine.
SUBSTANCE: invention refers to a method for HPLC-based determination of verapamil enantiomers in active pharmaceutical ingredients, tablets and blood plasma samples.
EFFECT: extended range of HPLC techniques for determination of verapamil enantiomers, simplified method as compared with common procedures, available reproduction and reduced research costs ensured by the optimal choice of the equipment and chemical agents.
1 cl, 6 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AMLODIPINE OPTICAL ISOMER SEPARATION METHOD | 2008 |
|
RU2357781C1 |
| METHOD FOR MODEL-DISCRIMINATIVE ESTIMATION OF PHARMACEUTICAL EQUIVALENCE OF DRUGS WITH ENTERIC COATING | 2016 |
|
RU2629397C2 |
| METHOD FOR ACTIVATING P450CYP3A4 ISOENZYME IN PATIENTS WITH CHRONIC CARDIAC FAILURE | 2014 |
|
RU2554775C1 |
| METHOD OF DETECTING ENANTIOMERS OF PRIMARY AMINE COMPOUNDS | 2006 |
|
RU2394236C2 |
| METHOD FOR QUANTITATIVE DETERMINATION OF DEXAMETHASONE IN BIOLOGICAL MEDIA USING HPLC WITH ULTRAVIOLET DETECTION | 2022 |
|
RU2792274C1 |
| METHOD OF PRODUCING ENANTIOMERICALLY PURE (S)-AMINO ACIDS ON BASIS OF [(S)-BPB-Gly]Ni(II) COMPLEX, DIRECTLY BONDED WITH FULLERENE CORE THROUGH α-CARBON ATOM IN FORM OF CHIRAL (A) AND (C) 1,4-ADDUCTS OF [60]FULLERENE | 2015 |
|
RU2614247C2 |
| METHOD FOR DETERMINING AMIODARONE AND ITS MAIN METABOLITE DESETHYLAMIODARONE IN HUMAN BLOOD SERUM | 2020 |
|
RU2749566C1 |
| DOSAGE FORM OF DNA-APTAMER | 2019 |
|
RU2730000C1 |
| 3,11b-CIS-DIHYDROTETRABENAZINE FOR TREATMENT OF PROLIFERATIVE DISEASE OR INFLAMMATION | 2006 |
|
RU2409364C2 |
| METHOD FOR DETERMINING LOSARTAN, ITS MAIN METABOLITE LOSARTAN CARBOXYLIC ACID AND GLIBENCLAMIDE IN HUMAN BLOOD SERUM AND URINE | 2020 |
|
RU2749567C1 |
